ERBB2 and breast carcinoma: HER2-positive breast cancer is considered an immunogenic tumor, and the host immune response in this breast cancer subtype has been extensively explored due to its known role in modulating the activity of anti-HER2 agents [e.g., through antibody-dependent cellular cytotoxicity (ADCC)]7,8.